ArticleInvestigative ophthalmology & visual science2026
Epigenetic Modulation of Thyroid-Stimulating Hormone Receptor Expression in Orbital Fibroblasts From Graves' Ophthalmopathy: Target for Treatment.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to investigate the expression and function of DNA methyltransferases (DNMTs) and histone methyltransferase EZH2 in regulating the expression of thyroid-stimulating hormone receptor (TSHR) and fibrotic markers by orbital fibroblasts from Graves' ophthalmopathy (GO) patients. Methods: DNMTs mRNA levels were measured in orbital fibroblasts from healthy controls (control orbital fibroblasts), active GO fibroblasts, and inactive GO fibroblasts (iGOFs). TSHR and other fibrotic markers were measured in iGOFs treated with platelet-derived growth factor (PDGF)-BB and decitabine (a DNMT inhibitor) or DZNep (an EZH2 inhibitor) or small interfering RNA by RT-qPCR or Western blotting. Results: DNMT1 and DNMT3A mRNA expressions were significantly higher in active GOFs compared with iGOFs and control orbital fibroblasts. Among all DNMTs, DNMT1 expression was at the highest levels. Upon PDGF-BB stimulation, DNMT1 and DNMT3A mRNA levels in iGOFs were significantly induced. Decitabine significantly inhibited PDGF-BB-induced cell viability and TSHR mRNA levels in iGOFs, whereas DNMT1 silencing partly reduced TSHR protein. Because a positive correlation between DNMT1 and EZH2 expression in iGOF was observed, the regulatory role of EZH2 on TSHR expression was also investigated. DZNep slightly decreased TSHR mRNA expression in iGOFs and iGO orbital tissue, whereas EZH2 silencing partly affects TSHR expression. Conclusions: This study demonstrates that DNMT1 is the major DNMT during the active stage of GO. Moreover, DNMT1 is inducible upon PDGF-BB stimulation in iGOFs, suggesting an important role of PDGF-BB and DNMT1 during an active stage of GO. Our findings also highlighted that the inhibition of DNMT or EZH2 potentially suppressed TSHR mRNA expression, suggesting potential therapies targeting DNMT/EZH2 in controlling GO progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.